Navigation Links
ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Date:4/23/2009

, its effectiveness at managing its financial resources, its ability to enter into transactions around its product candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its product candidates, regulatory developments involving its product candidates and its ability to obtain additional funding to support its operations. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2008. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
2. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
3. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
9. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
10. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
11. Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients ... to a recent online survey* sponsored by Mission Pharmacal ... the National Osteoporosis Foundation online support community, revealed that ... medication that comes in a form other than a ...
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... CITY, Feb. 21, 2012 Genomma Lab Internacional, S.A.B. de ... a non-binding proposal to acquire all of the outstanding shares ... ) common stock for $16.60 dollars per share in cash. ... including Prestige,s net debt. Genomma,s all-cash proposal ...
... Corporation (NYSE: SHP ) ("ShangPharma" or the ... development outsourcing company, today announced that it will attend ... in Boston, Massachusetts from March 5-7, 2012. ... Relations of ShangPharma, will present at the conference and ...
Cached Medicine Technology:Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 2Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 3Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 4Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 5
(Date:4/18/2014)... scientists could lead to potential new treatments for breaking ... , Fibrosis, or scarring, is a hallmark of ... lungs can lead to serious organ damage and, in ... options centers on findings made by Swati Bhattacharyya, PhD, ... that a specific protein plays in promoting fibrosis. ...
(Date:4/17/2014)... identified new pain relief targets that could be ... researchers at King,s College London made the discovery ... the periphery of the body. , Dr Marzia ... mechanisms underlying pain generation and our findings could ... effects." , One potential side effect of some ...
(Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
(Date:4/17/2014)... University synthetic biology team has created a new ... therapeutics that could travel the body and selectively ... Engineering cell-based, biological devices that monitor and modify ... synthetic biology. However, no existing technology enabled bioengineers ... physiological state and respond in a customized fashion. ...
(Date:4/17/2014)... The cause of neuronal death in Parkinson,s disease is ... may be mistaken for foreign invaders and killed by ... autoimmune diseases like type I diabetes, celiac disease, and ... published April 16, 2014, in Nature Communications . ... in Parkinson,s disease; but if true, it could lead ...
Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2
... , ... ... ... ...
... are beginning to find out why people with Parkinson,s ... harder to recognize expressions of emotion in other people,s ... American Psychological Association. One of the studies raises ... treatment for patients who no longer respond to medication, ...
... ... Innovative Set of Sales and Lead Cycle Management Technology , ... (PRWEB) March 3, 2010 -- References-Online, pioneer and leader in ... RO|Innovation (ROI). The name and brand identity shift reflects the expanded suite of ...
... , ... ... ... ...
... ... ... , ... , , ...
... already shown to be effective in breast cancer packs an ... have a specific genetic mutation, a study at UCLA,s Jonsson ... Tykerb when given together proved to significantly inhibit tumor growth ... a mutation that results in an aggressive form of the ...
Cached Medicine News:Health News:AUA Foundation Responds to American Cancer Society Guideline for the Early Detection of Prostate Cancer 2Health News:AUA Foundation Responds to American Cancer Society Guideline for the Early Detection of Prostate Cancer 3Health News:Parkinson's disease makes it harder to figure out how other people feel 2Health News:Parkinson's disease makes it harder to figure out how other people feel 3Health News:Embodying an Evolving Solution Set, References-Online is Now RO|Innovation 2Health News:Embodying an Evolving Solution Set, References-Online is Now RO|Innovation 3Health News:'Sharing Miracles' Television Program to Feature Legendary College Football Coach Bobby Bowden 2Health News:'Sharing Miracles' Television Program to Feature Legendary College Football Coach Bobby Bowden 3Health News:'Sharing Miracles' Television Program to Feature Legendary College Football Coach Bobby Bowden 4Health News:'Sharing Miracles' Television Program to Feature Legendary College Football Coach Bobby Bowden 5Health News:'Sharing Miracles' Television Program to Feature Legendary College Football Coach Bobby Bowden 6Health News:'Sharing Miracles' Television Program to Feature Legendary College Football Coach Bobby Bowden 7Health News:'Sharing Miracles' Television Program to Feature Legendary College Football Coach Bobby Bowden 8Health News:'Sharing Miracles' Television Program to Feature Legendary College Football Coach Bobby Bowden 9Health News:'Sharing Miracles' Television Program to Feature Legendary College Football Coach Bobby Bowden 10Health News:'Sharing Miracles' Television Program to Feature Legendary College Football Coach Bobby Bowden 11Health News:'Sharing Miracles' Television Program to Feature Legendary College Football Coach Bobby Bowden 12Health News:'Sharing Miracles' Television Program to Feature Legendary College Football Coach Bobby Bowden 13Health News:'Sharing Miracles' Television Program to Feature Legendary College Football Coach Bobby Bowden 14Health News:'Sharing Miracles' Television Program to Feature Legendary College Football Coach Bobby Bowden 15Health News:'Sharing Miracles' Television Program to Feature Legendary College Football Coach Bobby Bowden 16Health News:Vermillion Announces the Appointment of Carl Severinghaus to Board of Directors 2Health News:Vermillion Announces the Appointment of Carl Severinghaus to Board of Directors 3Health News:Vermillion Announces the Appointment of Carl Severinghaus to Board of Directors 4Health News:Vermillion Announces the Appointment of Carl Severinghaus to Board of Directors 5Health News:Herceptin and Tykerb effective against a subset of gastric cancers 2Health News:Herceptin and Tykerb effective against a subset of gastric cancers 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: